ST. LOUIS & SAN DIEGO–(BUSINESS WIRE)–Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of ready-to-use cell therapies to treat a wide range of hematological and solid malignancies, today presented preclinical data on WU- The company’s drug NK-101, the lead memory natural killer (NK) cell therapy product, during a poster session at the European Society for Medical Oncology (ESMO) Congress 2022, to be held in Paris, France, from September 9 to 13, 2022.
“We are pleased to present these data and build on the growing body of evidence validating our best-in-class memory NK cell platform,” said Dan Kemp, Ph.D., President and CEO of Wugen. “Today’s findings are an important step forward as we continue to advance WU-NK-101 in clinical development for solid tumors and acute myeloid leukemia (AML). »
“While adoptive cell therapies have proven to be a powerful tool against hematological cancers, their application to solid tumors has historically been limited by restricted cell trafficking to tumors and the severe tumor microenvironment (TME),” added Sergio Rutella, MD. , Ph.D., FRCPath, FRSB, Professor of Cancer Immunotherapy at Nottingham Trent University and Presenting Author. “These results are very promising and suggest that memory NK cells can circumvent these challenges, with broad potential therapeutic applications for solid tumors.
Today’s presentation highlighted the following points:
WU-NK-101 exhibited improved metabolic fitness and metabolic flexibility, contributing to resilient and improved function within the adverse immunosuppressive TME compared to conventional natural killer (cNK) cells.
WU-NK-101 showed potent cytotoxicity against tumor cells. In vitro, WU-NK-101 in combination with monoclonal antibodies (mAbs) demonstrated a statistically significant increase in antibody-dependent cellular cytotoxicity (ADCC) activity compared to mAbs alone, which was validated by anti-tumor activity significant live compared to WU-NK-101 alone.
WU-NK-101 in combination with mAbs demonstrated robust anti-tumor activity, showing increased trafficking, tumor infiltration and persistence.
These data suggest that WU-NK-101 could overcome the current limitations of adoptive cell therapies and support its clinical development in the context of solid tumors.
Details of Wugen’s presentation at ESMO are as follows:
- Title: WU-NK-101: An enhanced NK cell therapy optimized to work in the tumor microenvironment (TME)
- Abstract number: 11P
- Date and time: Sunday, September 11, 2022, 12:00 p.m. to 1:00 p.m. CEST (6:00 a.m. to 7:00 a.m. EDT)
- Location: Paris Expo Porte De Versailles, Posters Area, Hall 4
Additional information about the meeting is available at https://www.esmo.org/.
WU-NK-101 is a novel immunotherapy harnessing the power of natural killer (NK) memory cells to treat liquid and solid tumors. Memory NK cells are hyper-functional and long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-mediated memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferative capacity, and metabolic fitness that makes it better suited for cancer treatment than other NK cell therapies. Wugen applies its proprietary Moneta technologyMT platform to advance WU-NK-101 as a commercially scalable, ready-to-use cell therapy for cancer. WU-NK-101 is currently in development for acute myeloid leukemia (AML) and solid tumors.
Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of ready-to-use natural killer (NK) and CAR-T cell therapies for cancer. Wugen takes advantage of its owner MonetaMT platform and deep expertise in genomic engineering to launch a new class of memory NK cell therapies with a cytokine-mediated memory-like (CIML) phenotype, specifically designed to treat hematological and solid malignancies. For more information, visit www.wugen.com.